AbbVie Management

Management Kriterienprüfungen 2/4

AbbVie's CEO ist Rick Gonzalez, ernannt in Jan 2013, hat eine Amtszeit von 11.33 Jahren. Die jährliche Gesamtvergütung beträgt $25.66M, bestehend aus 6.6% Gehalt und 93.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.031% der Aktien des Unternehmens, im Wert von $86.14M. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 1.5 Jahre bzw. 11.3 Jahre.

Wichtige Informationen

Rick Gonzalez

Geschäftsführender

US$25.7m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.6%
Amtszeit als Geschäftsführer	11.4yrs
Eigentum des Geschäftsführers	0.03%
Durchschnittliche Amtszeit des Managements	1.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	11.4yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Rick Gonzalez im Vergleich zu den Einnahmen von AbbVie verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$26m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$9b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$26m	US$2m	US$12b
Sep 30 2022	n/a	n/a	US$13b
Jun 30 2022	n/a	n/a	US$13b
Mar 31 2022	n/a	n/a	US$12b
Dec 31 2021	US$24m	US$2m	US$11b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$7b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$24m	US$2m	US$5b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$22m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$5b
Dec 31 2018	US$21m	US$2m	US$6b
Sep 30 2018	n/a	n/a	US$8b
Jun 30 2018	n/a	n/a	US$6b
Mar 31 2018	n/a	n/a	US$6b
Dec 31 2017	US$23m	US$2m	US$5b

Vergütung im Vergleich zum Markt: RickDie Gesamtvergütung ($USD25.66M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt AR ($USD6.03M).

Entschädigung vs. Einkommen: RickDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Rick Gonzalez (70 yo)

11.4yrs

Amtszeit

US$25,661,972

Vergütung

Mr. Richard A. Gonzalez, also known as Rick, serves as Chairman of AbbVie Inc. and has been its Chief Executive Officer at AbbVie Inc. since 2013. Mr. Gonzalez served as an Executive Vice President of Phar...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Richard Gonzalez	Chairman & CEO	11.4yrs	US$25.66m	0.031% $ 92.5m
Robert Michael	President & COO	2yrs	US$14.44m	0.0056% $ 16.6m
Scott Reents	Executive VP & CFO	2yrs	US$10.19m	0.00087% $ 2.6m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.013% $ 38.1m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% $ 10.5m
Thomas Hudson	Senior VP & Chief Scientific Officer of Global Research	no data	keine Daten	0.0061% $ 18.1m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	keine Daten	keine Daten
Perry Siatis	Executive VP	1.7yrs	keine Daten	0% $ 0
Sanjay Narayan	Senior VP	less than a year	keine Daten	keine Daten
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% $ 2.3m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	less than a year	keine Daten	keine Daten
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.4yrs	keine Daten	0.0032% $ 9.4m

1.5yrs

Durchschnittliche Betriebszugehörigkeit

56yo

Durchschnittliches Alter

Erfahrenes Management: ABBVDDas Führungsteam des Unternehmens gilt nicht als erfahren (1.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Richard Gonzalez	Chairman & CEO	11.4yrs	US$25.66m	0.031% $ 92.5m
Roxanne Austin	Independent Director	11.4yrs	US$388.39k	0.00065% $ 1.9m
Thomas Freyman	Independent Director	4.1yrs	US$389.98k	0.0071% $ 21.1m
Glenn Tilton	Lead Independent Director	11.4yrs	US$421.58k	0.0014% $ 4.2m
Edward Rapp	Independent Director	11.4yrs	US$394.98k	0.00091% $ 2.7m
William H. Burnside	Independent Director	11.4yrs	US$377.48k	0% $ 0
Frederick Waddell	Independent Director	11.4yrs	US$369.98k	0.00011% $ 327.5k
Melody Meyer	Independent Director	7.1yrs	US$369.98k	0% $ 0
Brett Hart	Independent Director	8.4yrs	US$384.98k	0% $ 0
Rebecca Roberts	Independent Director	6.1yrs	US$359.98k	keine Daten
Robert Alpern	Independent Director	11.4yrs	US$461.18k	0.000010% $ 29.8k
Jennifer Davis	Independnet Director	less than a year	US$45.00k	keine Daten

11.4yrs

Durchschnittliche Betriebszugehörigkeit

70yo

Durchschnittliches Alter

Erfahrener Vorstand: ABBVDDie Vorstandsmitglieder sind sehr erfahren ( 11.3 ).

AbbVie Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie Inc. Announces Chief Executive Officer Changes

AbbVie Inc. Announces Director Appointments

Recent updates

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

AbbVie Announces U.S. Food and Drug Administration and European Medicines Agency Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

AbbVie Announces Results Evaluating the Efficacy, Safety, and Tolerability of UBRELVY

Abbvie Inc. Declares Quarterly Dividend, Payable on February 15, 2024

Lupus Therapeutics Partners with AbbVie Inc. on Clinical Trial Recruitment Efforts in SLE Through Lucin Lupus Clinical Trial Network

Abbvie Inc. Epkinly™ (Epcoritamab Injection/Epcoritamab for Injection) Receives Health Canada Authorization with Conditions as the First and Only Subcutaneous Bispecific Antibody to Treat Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl)

AbbVie Presents Positive Results from Head-to-Head Phase 3 Sequence Study in Crohn's Disease Meets All Primary and Secondary Endpoints

AbbVie Inc. Announces Director Appointments

AbbVie Inc. Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (Upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

AbbVie Inc. (NYSE:ABBV) acquired Mitokinin, Inc. for $655 million.

AbbVie Inc. to Report Q3, 2023 Results on Oct 27, 2023

Abbvie Presents Results from Phase 3 Canova Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma

AbbVie Announces European Commission Approval of TEPKINLY (epcoritamab) for Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Abbvie Inc. Announces Top-Line Results from the Phase 3 Sequence Clinical Trial Evaluating Risankizumab

AbbVie Inc. Declares Quarterly Dividend, Payable on November 15, 2023

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter